"Endgame" Issues for the Global Polio Eradication Initiative
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The polio eradication initiative, created after the World Health Assembly resolved, in 1988, to eradicate poliomyelitis globally by 2000, has made remarkable progress. From 1988 through 2000, the number of countries where polio was endemic decreased from >125 to 20, and the estimated number of polio cases decreased from 350,000 to <3500, for a percentage decrease of >99%. Wild-type 2 poliovirus has not been detected worldwide since October 1999, despite improving surveillance. The major focus of the eradication effort is to complete the task of stopping wild-type poliovirus transmission. Given the rapid progress made toward this goal, planning for the posteradication era has begun in earnest (1) to minimize the risk of reintroduction of virus into the population from laboratory stocks or long-term carriers, and (2) to prevent vaccine-derived polioviruses from circulating and causing outbreaks. This report summarizes the current thinking about these "endgame" issues, as put forth by the World Health Organization's technical advisory body for the initiative, the Technical Consultative Group on the Global Eradication of Poliomyelitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, there is no clear evidence of spread of iVDPVs from immunodeficient patients to the wider community (57, 63, 68).”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [63]
In the citing paper
“The number of viable options for the endgame strategy using the existing poliovirus vaccines now appears to be quite limited (12, 38, 63).”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [63]
In the citing paper
“Consequently, early detection of any future type 2 cVDPV outbreaks will require maintenance, and possible augmentation in some countries (54), of the present very high global standard for AFP and poliovirus surveillance (63, 72).”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [63]
In the citing paper
“Transition from OPV to IPV is likely to continue in polio-free countries, especially in developed countries in temperate zones where IPV efficacy is highest (67) and where high rates of IPV coverage can be maintained through routine immunization (63).”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [63]
In the citing paper
“The recognition that cVDPVs can cause polio outbreaks and potentially reestablish polio endemicity to polio-free areas has prompted a reassessment of global strategies for maintaining polio-free status after wild poliovirus circulation has ceased (12, 15, 38, 63, 68).”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [63]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Strebel, P. M., Sutter, R. W., Cochi, S. L., Biellik, R. J., Brink, E. W., Kew, O. M., Pallansch, M. A., Orenstein, W. A., & Hinman, A. R. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.2.568 · Cited by 337
WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines (1997) · Journal of Infectious Diseases · doi:10.1093/infdis/175.supplement_1.s215 · Cited by 88
The Polio Eradication Effort: Should Vaccine Eradication Be Next?
Dove, A. W., & Racaniello, V. R. (1997) · Science · doi:10.1126/science.277.5327.779 · Cited by 71
Research works printed but not linked: 12
- 2001, MMWR. Morbidity and mortality weekly report, 50, 320
- 1998, Weekly epidemiological record / Health Section of the Secretariat of the League of Nations, 73, 113
- 2001, 67, 397
- 2001, MMWR. Morbidity and mortality weekly report, 50, 620
- 1962, BMJ, i, 743
- 2001, International Journal of Epidemiology, 20, 1029
- 2000, MMWR. Morbidity and mortality weekly report, 49, 156
- 2001, MMWR. Morbidity and mortality weekly report, 50, 147
- 2001, MMWR. Morbidity and mortality weekly report, 50, 874
- 2001, MMWR. Morbidity and mortality weekly report, 50, 41
- 2001, Bulletin of the World Health Organization, 78, 347
- 2001, Clinical Infectious Diseases, 33, 79
Cited by
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703
Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993
Yang, C.-F., Naguib, T., Yang, S.-J., Nasr, E., Jorba, J., Ahmed, N., Campagnoli, R., van der Avoort, H., Shimizu, H., Yoneyama, T., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8366-8377.2003 · Cited by 233
Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication
Tebbens, R. J. D., Pallansch, M. A., Kew, O. M., Cáceres, V. M., Jafari, H., Cochi, S. L., Sutter, R. W., Aylward, R. B., & Thompson, K. M. (2006) · Risk Analysis · doi:10.1111/j.1539-6924.2006.00827.x · Cited by 174
Fractional Doses of Inactivated Poliovirus Vaccine in Oman
Mohammed, A. J., AlAwaidy, S., Bawikar, S., Kurup, P. J., Elamir, E., Shaban, M. M. A., Sharif, S. M., van der Avoort, H. G. A. M., Pallansch, M. A., Malankar, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909383 · Cited by 172
Sutter, R. W., Kew, O. M., & Cochi, S. L. (2008) · Vaccines · doi:10.1016/b978-1-4160-3611-1.50030-1 · Cited by 167
Economic analysis of the global polio eradication initiative
Tebbens, R. J. D., Pallansch, M. A., Cochi, S. L., Wassilak, S. G. F., Linkins, J., Sutter, R. W., Aylward, R. B., & Thompson, K. M. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.026 · Cited by 165
MacLennan, C., Dunn, G., Huissoon, A. P., Kumararatne, D. S., Martin, J., O'Leary, P., Thompson, R. A., Osman, H., Wood, P., Minor, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16150-3 · Cited by 162
Priming after a Fractional Dose of Inactivated Poliovirus Vaccine
Resik, S., Tejeda, A., Sutter, R. W., Diaz, M., Sarmiento, L., Alemañi, N., Garcia, G., Fonseca, M., Hung, L. H., Kahn, A.-L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1202541 · Cited by 139
Circulation of type 1 vaccine-derived poliovirus in the philippines in 2001
Shimizu, H., Thorley, B., Paladin, F. J., Brussen, K. A., Stambos, V., Yuen, L., Utama, A., Tano, Y., Arita, M., Yoshida, H., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.24.13512-13521.2004 · Cited by 146
Polio eradication: the OPV paradox
Dowdle, W. R., De Gourville, E., Kew, O. M., Pallansch, M. A., & Wood, D. J. (2003) · Reviews in Medical Virology · doi:10.1002/rmv.401 · Cited by 144
Sutter, R. W., Kew, O. M., Cochi, S. L., & Aylward, R. B. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00035-5 · Cited by 85
The Risks, Costs, and Benefits of Possible Future Global Policies for Managing Polioviruses
Thompson, K. M., Tebbens, R. J. D., Pallansch, M. A., Kew, O. M., Sutter, R. W., Aylward, R. B., Watkins, M., Gary, H. E., Alexander, J. P., Jafari, H. S., et al. (2008) · American Journal of Public Health · doi:10.2105/ajph.2007.122192 · Cited by 81
Global health goals: lessons from the worldwide effort to eradicate poliomyelitis
Aylward, R. B., Acharya, A. K., England, S., Agocs, M. M., & Linkins, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14337-1 · Cited by 77
Korotkova, E. A., Park, R., Cherkasova, E. A., Lipskaya, G. Y., Chumakov, K. M., Feldman, E. V., Kew, O. M., & Agol, V. I. (2003) · Journal of Virology · doi:10.1128/jvi.77.23.12460-12465.2003 · Cited by 73
Synthesizing epidemiological and economic optima for control of immunizing infections
Klepac, P., Laxminarayan, R., & Grenfell, B. T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101694108 · Cited by 73
Duration of serologic response to three viral antigens in cats
Mouzin, D. E., Lorenzen, M. J., Haworth, J. D., & King, V. L. (2004) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.2004.224.61 · Cited by 73
Poliomyelitis Eradication--a Dangerous Endgame
Nathanson, N., & Fine, P. (2002) · Science · doi:10.1126/science.1071207 · Cited by 67
OPV Cessation--the Final Step To a "Polio-Free" World
Aylward, R. B., Sutter, R. W., & Heymann, D. L. (2005) · Science · doi:10.1126/science.1115547 · Cited by 63
Risk Management in a Polio‐Free World
Aylward, R. B., Sutter, R. W., Cochi, S. L., Thompson, K. M., Jafari, H. S., & Heymann, D. (2006) · Risk Analysis · doi:10.1111/j.1539-6924.2006.00840.x · Cited by 51
El‐Tahtawy, A., Glue, P., Andrews, E. N., Mardekian, J., Amsden, G. W., & Knirsch, C. A. (2008) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000236 · Cited by 50
Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future
Patel, M. M., & Cochi, S. L. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix117 · Cited by 46
Hidalgo, S., Erro, M. G., Cisterna, D., & Freire, M. C. (2003) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000069792.60744.5b · Cited by 44
Multiplex PCR Method for Identifying Recombinant Vaccine-Related Polioviruses
Kilpatrick, D. R., Ching, K., Iber, J., Campagnoli, R., Freeman, C. J., Mishrik, N., Liu, H.-M., Pallansch, M. A., & Kew, O. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.9.4313-4315.2004 · Cited by 39
The Costs of Future Polio Risk Management Policies
Tebbens, R. J. D., Sangrujee, N., & Thompson, K. M. (2006) · Risk Analysis · doi:10.1111/j.1539-6924.2006.00842.x · Cited by 37
Emergence of Vaccine-derived Polioviruses, Democratic Republic of Congo, 2004–2011
Gumede, N., Lentsoane, O., Burns, C. C., Pallansch, M. A., de Gourville, E. M., Riziki, Y., Muyembe-Tamfum, J. J., Puren, A. J., Schoub, B. D., & Venter, M. (2013) · Emerging infectious diseases · doi:10.3201/eid1910.130028 · Cited by 35
The cost-effectiveness of alternative polio immunization policies in South Africa
Griffiths, U. K., Botham, L., & Schoub, B. D. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.032 · Cited by 34
Microbe hunting in the 21st century
Lipkin, W. I. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811420106 · Cited by 31
Khetsuriani, N., Helfand, R. F., Pallansch, M. A., Kew, O. M., Fowlkes, A., Oberste, M. S., Tukei, P. M., Muli, J., Makokha, E. P., & Gary, H. E. (2009) · BMC Infectious Diseases · doi:10.1186/1471-2334-9-136 · Cited by 30
West Nile virus and “poliomyelitis”
Sejvar, J. J. (2004) · Neurology · doi:10.1212/01.wnl.0000130361.62281.69 · Cited by 30
Genomic Analysis of Recombinant Sabin Clinical Isolates
Paximadi, E., Karakasiliοtis, I., Mamuris, Z., Stathopoulos, C., Krikelis, V., & Markoulatos, P. (2006) · Virus Genes · doi:10.1007/s11262-005-6877-1 · Cited by 30
McRae, J. E., Quinn, H., Saravanos, G. L., Carlson, S., Britton, P. N., Crawford, N. W., Wood, N. J., Marshall, H. S., Macartney, K. K., & The Paediatric Active Enhanced Disease Surveillance (PAEDS) network (2020) · Communicable Diseases Intelligence · doi:10.33321/cdi.2020.44.49 · Cited by 20
Decision Analysis in Planning for a Polio Outbreak in the United States
Jenkins, P. C., & Modlin, J. F. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2358 · Cited by 19
Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa
Pavlov, D. N., van Zyl, W. B., Heerden, J. V., Kruger, M., Blignaut, L., Grabow, W. O. K., & Ehlers, M. M. (2006) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2006.03020.x · Cited by 19
Hu, Y., Xu, K., Han, W., Chu, K., Jiang, D., Wang, J., Tian, X., Ying, Z., Zhang, Y., Li, C., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz380 · Cited by 18
Nomoto, A., & Arita, I. (2002) · Nature Immunology · doi:10.1038/ni0302-205 · Cited by 17
Kim, S. J., Kim, S., Jee, Y. M., & Kim, J. S. (2007) · Journal of Korean Medical Science · doi:10.3346/jkms.2007.22.2.362 · Cited by 17
Towards global poliomyelitis eradication: The successes and challenges for a developed country
Wood, N. J., & Thorley, B. R. (2003) · Journal of Paediatrics and Child Health · doi:10.1046/j.1440-1754.2003.00263.x · Cited by 16
Lagos, R., Hoffenbach, A., Scemama, M., Dupuy, M., Schödel, F. P., Hessel, L., & Levine, M. M. (2005) · Human Vaccines · doi:10.4161/hv.1.3.1848 · Cited by 15
The Mechanism of Poliovirus Eradication
Kew, O. M., & Pallansch, M. A. (2014) · Molecular Biology of Picornavirus · doi:10.1128/9781555817916.ch39 · Cited by 12
ENTEROVIRUSES AND PARECHOVIRUSES
Cherry, J. D., & Krogstad, P. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50183-7 · Cited by 11
Hassan, J., Wangai, L. N., Borus, P., Khayeka‐Wandabwa, C., Karani, L. W., Kithinji, M., & Kiptoo, M. K. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2843-y · Cited by 10
Chu, K., Han, W., Jiang, D., Jiang, Z., Zhu, T., Xu, W., Hu, Y., & Zeng, G. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1919091 · Cited by 9
Prevots, D. R., Pascual, F. B., Angellili, M. L., Brayden, R. M., Irigoyen, M., LaRussa, P. S., Sawyer, M. H., Baughman, A. L., & Pallansch, M. A. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000143641.27336.2e · Cited by 8
[Portugal and Europe are poliomyelitis free].
Gonçalves, G., Santos, L. A., Sarmento, A., Rocha, G., & Valente, P. (2003) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.20344/amp.1140 · Cited by 7
Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells
Haastrup, E. K., Thierry-Carstensen, B., Jensen, A. M., Stellfeld, M., & Heilmann, C. J. (2003) · Vaccine · doi:10.1016/j.vaccine.2003.09.011 · Cited by 7
Baseline patterns of bone scintigraphy in patients with established post-poliomyelitis paralysis
Marafi, F., Ali, A. A.-S., Esmail, A. A. H., & Elgazzar, A. H. (2009) · Skeletal Radiology · doi:10.1007/s00256-009-0739-1 · Cited by 6
Enteroviruses, Parechoviruses, and Saffold Viruses
Krogstad, P. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00166-7 · Cited by 6
Challenges in the final stage of polio eradication
Basu, R. N. (2004) · The Indian Journal of Pediatrics · doi:10.1007/bf02724101 · Cited by 6
WHO global action plan for laboratory containment of wild polioviruses (Second edition)
Shimizu, H., Yoshida, H., & Miyamura, T. (2005) · Uirusu · doi:10.2222/jsv.55.161 · Cited by 6
Perspectivas en la erradicación de las infecciones prevenibles por vacunación
Navarro-Alonso, J.-A., & Fernández, J. A. (2002) · Medicina Clínica · doi:10.1016/s0025-7753(02)73503-3 · Cited by 4
Editorial: Polio eradication in Australia and the world
ROCHE, P. W., & Spencer, J. D. (2002) · Communicable Diseases Intelligence · doi:10.33321/cdi.2002.26.13 · Cited by 4
Polio eradication—rethinking the endpoint of the end game
Khuri-Bulos, N. A. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)00999-5 · Cited by 3
Eliminación de los virus de la poliomielitis, ¿está a nuestro alcance?
Navarro, J. A. (2005) · Vacunas · doi:10.1016/s1576-9887(05)73023-5 · Cited by 2
Nates, S. V., FRIAS, M., Belfiore, S. M., Isa, M. B., Martínez, L. C., Chuit, R., Armoni, J., & Luxemburger, C. (2010) · Epidemiology and Infection · doi:10.1017/s0950268810001512 · Cited by 2
Khan, M. M. (2009) · Springer eBooks · doi:10.1007/978-0-387-78665-0_78 · Cited by 2
Modlin, J. F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00171-5 · Cited by 1
Incorporating economic constraints for optimal control of immunizing infections
Huang, Y.-J., Hsiao, A.-T., & Juang, J. (2022) · Chaos An Interdisciplinary Journal of Nonlinear Science · doi:10.1063/5.0083312 · Cited by 1
La erradicación de la poliomielitis está próxima
Vaqué, J., & Moreno, N. (2003) · Vacunas · doi:10.1016/s1576-9887(03)70338-0 · Cited by 1
Moon, R. Y. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544798.013
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01311-1
(2010) · Elsevier eBooks · doi:10.1016/b978-0-444-53272-5.50009-1
Dittmann, S. (2002) · Side effects of drugs annual · doi:10.1016/s0378-6080(02)80039-3
(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00546-5
Abrams, E. J., Moon, R. Y., Robinson, L.-G. E., & Dyke, R. B. V. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544781.007
Ανασυνδυασμένα στελέχη πολιοϊών - θέσεις γενετικού ανασυνδυασμού
Paximadi, E. (2009) · doi:10.12681/eadd/17217
Quantitative analysis of trade-offs and model input sensitivities in public health
Tebbens, R. J. D. (2005) · Research Repository (Delft University of Technology)
Crombie, I. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-2081-7_8
TABLET BASED VACCINES: A REVIEW OF RESEARCH AND DEVELOPMENT
Alieva, A. B., Aidarbekova, D. B., Almas, E. K., Serikbayov, O. N., Barakbayev, K. B., Chervyakova, O. V., & А.А., К. (2026) · Ġylym men densaulyķ saķtau. · doi:10.34689/sh.2026.28.2.023
Metadata
- Authors
- Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis
- Corresponding author
- Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-01-01
- Volume
- 34
- Issue
- 1
- Pages
- 72-77
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4255162284
- Cited by
- 61
- References
- 3
- Citations by year
- 2026: 1 · 2025: 2 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2017: 2 · 2015: 1 · 2014: 1 · 2013: 3
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- polio eradication, poliomyelitis, wild-type poliovirus, vaccine-derived poliovirus, polio surveillance
- MeSH terms
- Humans, Poliomyelitis, World Health Organization, Poliovirus Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.